6BIO |
G08-900 |
667463-62-9 |
C16H10BrN3O2 |
98% (TLC: 5% CH3OH3 in CH2Cl2, Rf=0.43); NMR (Conforms) |
(2'Z,3'E)-6-Bromoindirubin-3'-oxime |
7-CL-O-Nec-1 |
R07-901B |
852391-15-2 |
C13H12ClN3O |
>98% (TLC); NMR (Conforms) |
Nec-1s; 5-((7-Chloro-1H-indol-3-yl)methyl)-3-methylimidazolidine-2,4-dione |
A83-01 |
A09-900 |
909910-43-6 |
C25H19N5S |
>98% (TLC); NMR (Conforms) |
3-(6-Methyl-2-pyridinyl)-N-phenyl-4-(4-quinolinyl)-1H-pyrazole-1-carbothioamide |
AAL-993 |
F11-900C |
269390-77-4 |
C20H16F3N3O |
>98% (TLC); NMR (Conforms) |
2-((4-Pyridyl)methyl)amino-N-(3 (trifluoromethyl)phenyl)benzamide |
AG-1296 |
P12-900 |
146535-11-7 |
C16H14N2O2 |
>98% (TLC); NMR (Conforms) |
6,7-Dimethoxy-3-phenylquinoxaline |
AG-1478 |
E10-900B |
175178-82-2 |
C16H14ClN3O2 |
>98% (TLC); NMR (Conforms) |
1. N-(3-Chlorophenyl)-6,7-dimethoxy-4-quinazolinanine
2. Free Base
|
AG-1517 |
K11-900B |
153436-54-5 |
C16H14BrN3O2 ∙ HCl |
>98% (TLC); NMR (Conforms) |
1. 4-(3-Bromoanilino)-6,7-dimethoxyquinazoline hydrochloride
2. PD-153,035
3. SU-5271
4. ZM-252868 |
AG-490 |
J02-901 |
133550-30-8 |
C17H14N2O3 |
>98% (TLC); NMR (Conforms) |
(E)-2-Cyano-3-(3,4-dihydrophenyl)-N-(phenylmethyl)-2-propenamide |
AG-879 |
N28-909B |
148741-30-4 |
C18H24N2OS |
>99% (TLC); NMR (Conforms) |
alpha-Cyano-(3,5-di-t-butyl-4-hydroxy)thiocinnamide |
Alsterpaullone |
G09-901C |
237430-03-4 |
C16H11N3O3 |
>96% (TLC); NMR (Conforms) |
9-Nitro-7,12-dihydroindolo-[3,2-d][1] benzazepin-6(5)-one |
Amlexanox |
T02-901 |
68302-57-8 |
C16H14N2O4 |
>98% (TLC); NMR (Conforms) |
2-Amino-7-(1-methylethyl)-5-oxo-5H-[1]benzopyrano[2,3-b]pyridine-3-carboxylic acid |
Apigenin |
K10-900C |
520-36-5 |
C15H10O5 |
>98% (TLC); NMR (Conforms) |
4',5,7-Trihydroxyflavone |
AR-A014418 |
G09-901 |
487021-52-3 |
C12H12N4O4S |
>98% (TLC); NMR (Conforms) |
N-[(4-Methoxyphenyl) methyl]-N'-(5-nitro-2-thiazolyl) urea |
AS-041164 |
P29-901 |
6318-41-8 |
C11H7NO4S |
>98% (TLC); NMR (Conforms) |
1. 5-Benzo[1,3]dioxol-5-ylmethylene-thiazolidine-2,4-dione
2. NSC31098
|
AS-605240 |
P27-901 |
648450-29-7 |
C12H7N3O2S |
>98% (TLC); NMR (conforms) |
5-(6-Quinoxalinylmethylene)-2,4-thiazolidine-2,4-dione |
BAY 11-7082 |
C51-900 |
19542-67-7 |
C10H9NO2S |
>98% (TLC); NMR (Conforms) |
(E)-3-[(4-methylphenylsulfonyl]-2-propenenitrile |
BML-259 |
C33-901 |
267654-00-2 |
C14H16N2OS |
>98% (TLC: 5% CH3OH/CH2Cl2; Rf=0.46); NMR (Conforms) |
N-(5-Isopropylthiazol-2-yl) phenylacetamide |
BML-277 |
C48-901 |
516480-79-8 |
C20H14ClN3O2 |
≥98% (TLC; 1:1 ethylacetate: hexane; Rf=0.17); NMR (Conforms) |
1. 2-(4-(4-chlorophenoxy)phenyl)-1H-benzimidazole-5-carboxamide
2. Chk2 Inhibitor II
|
BRD-7389 |
R15-901 |
376382-11-5 |
C24H18N2O2 |
>98% (TLC); NMR (Conforms) |
1-[(2-Phenylethyl)amino]-3H-naphtho[1,2,3-de]quinoline-2,7-dione |
CHIR-99021 |
G09-901B |
252917-06-9 |
C22H18Cl2N8 |
>98% (TLC); NMR (Conforms) |
6-[[2-[[4-(2,4-Dichlorophenyl)-5-(5-methyl-1H-imidazol-2-yl)-2-pyrimidinyl] amino] ethyl] amino]-3-pyridinecarbonitrile |
CID-2011756 |
P72-901 |
638156-11-3 |
C22H21ClN2O3 |
≥98% (TLC); NMR (Conforms) |
5-(3-Chlorophenyl)-N-[4-(4-morpholinylmethyl) phenyl]-2-furancarboxamide |
CZC-54252 HCl |
L10-901 |
1199911-27-9 |
C22H25ClN6O4S ∙ HCl |
≥98% (TLC); NMR (Conforms) |
N-[-[[5-Chloro-2-[[2-methoxy-4-(4-morpholinyl) phenyl] amino]-4-pyrimidinyl] amino] phenyl] methanesulfonamide hydrochloride |
Dabrafenib |
B08-901 |
1195765-45-7 |
C23H20F3N5O2S2 |
>98% (TLC); NMR (conforms) |
N-[3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluoro-benzenesulfonamide; GSK2118436 |
Dasatinib |
S19-901B |
302962-49-8 |
C22H26ClN7O2S |
>98% (TLC); NMR (Conforms) |
1. N-(2-chloro-6-methylphneyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino) thiazole-5-carboxamide;
2. BMS-354825 |
Deguelin |
A16-900B |
522-17-8 |
C23H22O6 |
>98% (TLC); NMR (Conforms) |
13,13aS-dihydro-9,10-dimethoxy-3,3-dimethyl-3H-[1]benzopyrano[3,4-b]pyrano[2,3-h][1]benzopyran-7(7aS)-one |
Dibutyryl cAMP |
P51-901 |
16980-89-5 |
C18H23N5O8P · Na |
>98% (HPLC); NMR (conforms) |
N6, O2’-Dibutyryl adenosine 3’, 5’-cyclic monophosphate sodium salt; Bucladesine Na |
Dimethylsphingosine |
S17-900 |
119567-63-4 |
C20H41NO2 |
>98% (TLC); NMR (Conforms) |
(2S,3R,E)-2-(dimethylamino)octadeca-4-ene-1,3,diol |
DMPQ 2 HCl |
P13-901 |
137206-97-4 |
C16H14N2O2 ∙2HCl |
>98% (TLC); NMR (Conforms) |
5,7-Dimethoxy-3-(4-pyridinyl) quinoline dihydrochloride |
Doramapimod |
M39-900 |
285983-48-4 |
C31H37N5O3 |
>98% (TLC); NMR (Conforms) |
1. 1-[5-tert-butyl-2-(4-methylphenyl) pyrazol-3-yl]-3-[4-(2-morpholin-4-ylethoxy) naphthalen-1-yl] urea
2. BIRB-796
|
Dorsomorphin |
P47-900 |
866405-64-3 |
C24H25N5O |
>98% (TLC); NMR (Conforms) |
1. 6-[4-[2-(1-Piperidinyl) ethoxy] phenyl]-3-(4-pyridinyl)-pyrazolo[1,5-a] pyrimidine
2. BML-275
|
Erlotinib HCl |
E10-900C |
183319-69-9 |
C22H23N3O4 ∙ HCl |
>98% (TLC); NMR (Conforms) |
N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine, hydrochloride |
Everolimus |
F17-901D |
159351-69-6 |
C53H83NO14 |
≥98% (HPLC); NMR (Conforms) |
40-O-(2-hydroxyethyl)rapamycin) |
Fasudil HCl |
R10-900 |
105628-07-7 |
C14H17N3O2S ∙ HCl |
>98% (TLC); NMR (Conforms) |
1. 1-(5-Isoquinolinesulfonyl) homopiperazine HCl
2. HA-1077 |
Flavopiridol HCl |
C22-900 |
131740-09-5 |
C21H20ClNO5 · HCl |
>98% (HPLC); NMR (Conforms) |
2-(2-Chlorophenyl)-5,7-dihydroxy-8-[(3S, 4R)-3-hydroxy-1-methyl-4-piperidinyl]-4H-1-benzopyran-4-one, hydrochloride; L 86-8275; Alvocidib; NSC-649890 |
Gefitinib |
E10-900 |
184475-35-2 |
C22H24ClFN4O3 |
>98% (TLC); NMR (Conforms) |
1. N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy) quinazolin-4-amine;
2. ZD1839 |
Genistein |
K11-900 |
446-72-0 |
C15H10O5 |
98% (TLC); NMR (Conforms) |
1. 5,7-Dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one
2. 4',5,7-Trihydroxyisoflavone |
GF-109203X |
P61-900 |
133052-90-1 |
C25H24N4O2 |
98% (TLC); NMR (Conforms) |
1. 2-[1-(3-Dimethylaminopropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl) maleimide
2. Bisindolylmaleimide I
|
GSK-690693 HCl |
A16-900 |
937174-76-0 |
C21H27N7O3 .HCl |
99% (HPLC); NMR (Conforms) |
(S)-4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol. HCl |
GW-441756 |
N28-909 |
504433-23-2 |
C17H13N3O |
98% (TLC: 5% CH3OH: CH2Cl2; Rf=0.4) mixture of E and Z isomers |
1,3-Dihydro-3-[(1-methyl-1H-indol-3-yl)methylene]-2H-pyrrolo[3,2-b]pyridin-2-one
|
GW-5074 |
R01-901B |
220904-83-6 |
C15H8Br2INO2 |
98% (TLC); NMR (Conforms) |
3-(3,5-Dibromo-4-hydroxy-benzylidene)-5-iodo-1,3-dihydro-indol-2-one |
GW2580 |
C74-901 |
870483-87-7 |
C20H22N4O3 |
≥98% (TLC); NMR (Conforms) |
5-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)pyrimidine-2,4-diamine |
H-89 2HCl |
P51-900B |
127243-85-0 |
C20H20BrN3O2S ∙ 2HCl |
>98% (TLC); NMR (Conforms) |
N-[2-[[3-(4-Bromophenyl)-2-propenyl] amino] ethyl]-5-isoquinolinesulfonamide dihydrochloride |
HA-100 2HCl |
K10-900F |
84468-24-6 |
C13H15N3O2S • 2HCl |
>98% (HPLC); NMR (conforms) |
5-(1-Piperazinylsulfonyl)isoquinoline dihydrochloride |
Hypericin |
P61-900C |
548-04-9 |
C30H16O8 |
>98% (TLC); NMR (Conforms) |
1,3,4,6,8,13-Hexahydroxy-10,11-dimethylphenanthro [1,10,9,8-opqra] perylene-7,14-dione |
IM-12 |
G09-901D |
1129669-05-1 |
C22H20FN3O2 |
>98% (HPLC); NMR (conforms) |
3-(4-Fluorophenylethylamino)-1-methyl-4-(2-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione |
Imatinib mesylate |
A03-901B |
220127-57-1 |
C29H31N7O · CH3SO3H |
98% (TLC); NMR (Conforms) |
1. 4-[(4-Methyl-1-piperazinyl) methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl] amino]-phenyl] benzamide methanesulfonate
2. STI-571
|
IQ-1S |
M35-901B |
1421610-21-0 |
C15H8N3O |
>98% (TLC); NMR (Conforms) |
11H-Indeno[1,2-b]quinoxalin-11-one oxime, sodium salt |
JX-401 |
M39-901 |
349087-34-9 |
C21H25NO2S |
>98% (TLC); NMR (Conforms) |
1-[2-Methoxy-4-(methylthio) benzoyl]-4-(phenylmethyl) piperidine |
K252A |
K10-900D |
99533-80-9 |
C27H21N3O5 |
>98% (TLC); NMR (Conforms) |
2,3,9S,10R,11,12R-hexahydro-10-hydroxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, methyl ester |
K252B |
K10-900E |
99570-78-2 |
C26H19N3O5 |
>98% (TLC); NMR (Conforms) |
(9S,10R,12R)-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid |
KT-5823 |
P78-900 |
126643-37-6 |
C29H25N3O5 |
>98% (TLC); NMR (Conforms) |
2,3,9,10,11,12-hexahydro-10R-methoxy-2,9-dimethyl-1-oxo-9S,12R-epoxy-1H-diindolo[1,2,3-fg:3’,2’,1’-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, methyl ester |
KT5720 |
P51-900 |
108068-98-0 |
C32H31N3O5 |
>98% (TLC); NMR (Conforms) |
2,3,9,10,11,12-hexahydro-10S-hydroxy-9-methyl-1-oxo-9R,12S-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, hexyl ester |
KU-55933 |
A26-901 |
587871-26-9 |
C21H17NO3S2 |
>98% (TLC); NMR (conforms) |
2-(4-Morpholinyl)-6-(1-thianthrenyl)-4H-pyran-4-one |
Lapatinib |
E10-900D |
231277-92-2 |
C29H26ClFN4O4S |
98% (TLC); NMR (Conforms) |
1. N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]-2-furyl]quinazolin-4-amine
2. GW-572016
|
Lenvatinib |
K01-901 |
417716-92-8 |
C21H19ClN4O4 |
>98% (TLC); NMR (conforms) |
4-[3-Chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-6-quinolinecarboxamide; E7080 |
Lestaurtinib |
F12-901 |
111358-88-4 |
C26H21N3O4 |
>98% (TLC); NMR (Conforms) |
1. CEP-701
2. KT-5555 |
LFM-A13 |
B10-901 |
62004-35-7 |
C11H8Br2N2O2 |
98% (TLC: 2:8 CH3OH:CH2Cl2; Rf=0.53); NMR (Conforms) |
2-Cyano-N-(2,5-dibromophenyl)-3-hydroxy-2-butenamide |
LH-846 |
C67-901 |
639052-78-1 |
C16H13ClN2OS |
>98% (TLC); NMR (Conforms) |
N-(5-Chloro-6-methyl-2-enzothiazolyl)benzeneacetamide |
Locostatin |
R01-901C |
133812-16-5 |
C14H15NO3 |
>98% (TLC); NMR (conforms) |
(4S)-3-[(E)-But-2-enoyl]-4-benzyl-2-oxazolidinone; UIC-1005 |
LY-294002 |
P27-900C |
154447-36-6 |
C19H17NO3 |
>98% (TLC); NMR (Conforms) |
2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one |
LY-364947 |
T07-901 |
396129-53-6 |
C17H12N4 |
>98% (TLC); NMR (Conforms) |
4-(3-Pyridin-2-yl-1H-pyrazol-4-yl)quinolone; HTS-466284 |
LYS6K2 |
R15-900 |
NF |
C21H19F4N7 |
>97% (HPLC); NMR (Conforms) |
4-(4-(4-(4-fluoro-3-(trifluoromethyl) phenyl)-1-methyl-1H-imidazol-2-yl) piperidin-1-yl)-1H-pyrazolo [3,4-d] pyrimidine |
MLS-573151 |
C08-909 |
NF |
C21H19N3O2S |
>98% (TLC); NMR (Conforms) |
4-[3,5-diphenyl-4,5-dihydropyrazol-1-yl] benzenesulfonamide |
Necrostatin-1 |
R07-901 |
4311-88-0 |
C13H13N3OS |
>98% (TLC: 1:9, CH3OH:CH2Cl2; Rf=0.6); NMR (Conforms) |
1. 5-(1H-Indol-3-ylmethyl)-3-methyl-2-thioxo-4-imidazolidinone
2. Methylthiohydantoin-DL-tryptophan
|
Nilotinib |
A03-901 |
641571-10-0 |
C28H22F3N7O |
>98% (TLC); NMR (Conforms) |
1. 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)- 5-(trifluoromethyl) phenyl]-3- [(4-pyridin-3-ylpyrimidin-2-yl) amino] benzamide
2. AMN-107 |
NPC-15437 |
P61-900B |
141774-20-1 |
C25H50N4O2 ∙ 2HCl |
98% (TLC); NMR (Conforms) |
(S)-2,6-Diamino-N-[(1-(1-oxotridecyl)-2-piperidinyl) methyl] hexanamide dihydrochloride hydrate |
NVP-BEZ235 |
F17-900 |
915019-65-7 |
C30H23N5O |
>98% (TLC); NMR (Conforms) |
2-Methyl-2-{4-[3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydro-1H-imidazo[4,5-c] quinolin-1-yl] phenyl} propanenitrile |
Parthenolide |
I03-901B |
20554-84-1 |
C15H20O3 |
>98% (TLC); NMR (conforms) |
Sesquiterpene lactone found in feverfew (Tanacetum parthenium) |
PD-325901 |
M02-901B |
391210-10-9 |
C16H14F3IN2O4 |
≥98% (HPLC); NMR (Conforms) |
N-[(2R)-2,3-Dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-benzamide |
PD-98059 |
M02-900 |
167869-21-8 |
C16H13NO3 |
>98% (TLC); NMR (Conforms) |
2-(2-Amino-3-methoxyphenyl)-4H-1-benzopyran-4-one; 2'-Amino-3'-methoxyflavone |
Phorbol-12-myristate-13 acetate |
P61-900D |
16561-29-8 |
C36H56O8 |
>99% (HPLC); NMR (conforms) |
12-O-Tetradecanoylphorbol-13-acetate; PMA; TPA |
Piceatannol |
I01-901 |
10083-24-6 |
C14H12O4 |
>98% (TLC); NMR (Conforms) |
3,3',4,5'-Tetrahydroxy-trans-stilbene |
Picropodophyllotoxin |
I02-901 |
477-47-4 |
C22H22O8 |
>97% (TLC); NMR (Conforms) |
(5R,5aS,8aR,9R)-5,8,8a,9-Tetrahydro-9-hydroxy-5-(3,4,5-trimethoxyphenyl)-furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one |
PKC-412 |
K10-900B |
120685-11-2 |
C35H30N4O4 |
>98% (TLC); NMR (Conforms) |
1. 4'-N-Benzoyl staurosporine
2. Midostaurin
3. CGP-41251 |
PP1 |
S19-900 |
172889-26-8 |
C16H19N5 |
98% (TLC); NMR (Conforms) |
4-Amino-1-tert-butyl-3-(4-methylphenyl) pyrazolo [3,4-d] pyrimidine |
PP2 |
S19-900B |
172889-27-9 |
C15H16ClN5 |
>98% (TLC); NMR (Conforms) |
3-(4-chlorophenyl) 1-(1,1-dimethylethyl)-1H-pyrazolo [3,4-d] pyrimidin-4-amine |
PX-866 |
P27-900 |
502632-66-8 |
C29H35NO8 |
>98% (TLC); NMR (Conforms) |
(1E,4S,4aR,5R,6aS,9aR)-5-(acetyloxy)-1-[(di-2-propen-1-ylamino) methylene]-4,4a,5,6,6a,8,9,9-a-octahydro-11-hydroxy-4-(methoxymethyl)-4a,6a-dimethyl-cyclopenta [5,6] naphtha [1,2-c] pyran-2,7,10(1H)-trione |
R-59022 |
D21-900 |
93076-89-2 |
C27H26FN3OS |
>98% (HPLC); NMR (conforms) |
6-[2-[4-[(4-Fluorophenyl)phenylmethylene]-1-piperidinyl]ethyl]-7-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one |
Rapamycin |
F17-901 |
53123-88-9 |
C51H79NO13 |
>98% (TLC: 10% CH3OH in CH2Cl2; Rf=0.51); NMR (Conforms) |
Sirolimus; Fermentation product |
Regorafenib |
K01-900 |
755037-03-7 |
C21H15ClF4N4O3 |
>98% (HPLC,TLC); NMR (conforms) |
4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-fluorophenoxy]-N-methyl-2-pyridinecarboxamide; BAY 73-4506 |
Reversine |
A28-900 |
656820-32-5 |
C21H27N7O |
>98% (HPLC, TLC); NMR (conforms) |
2-(4-Morpholinoanilino)-6-cyclohexylaminopurine |
Ro 31-6045 |
R21-901 |
113963-68-1 |
C21H15N3O2 |
>98% (HPLC, TLC); NMR (conforms) |
1-Methyl-3,4-bis(indol-3-yl)maleimide; Bisindolylmaleimide V; BIM V |
Roscovitine |
C22-901 |
186692-46-6 |
C19H26N6O |
>99% (TLC); NMR (Conforms) |
(R)-2-((6-(benzylamino)-9-isopropyl-9H-purin-2-yl) amino) butan-1-ol |
Ruxolitinib |
J01-901 |
941678-49-5 |
C17H18N6 |
>98% (HPLC,TLC); NMR (conforms) |
(3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile |
SB-202190 |
M39-900B |
152121-30-7 |
C20H14N3OF |
>98% (TLC: 10% CH3OH in CH2Cl2, Rf=0.25); NMR (Conforms) |
4-[4-(4-Fluorophenyl)-5-(4-pyridinyl)-1H-imidazol-2-yl] phenol |
SB-203580 |
M39-900C |
152121-47-6 |
C21H16N3OSF |
>98% (TLC); NMR (Conforms) |
4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl) imidazole |
SC-514 |
I03-901 |
354812-17-2 |
C9H8N2OS2 |
>98% (TLC; 5% CH3OH in CH2Cl2; Rf=0.27); NMR (Conforms) |
5-(Thien-3-yl)-3-aminothiophene-2-carboxamide |
Sorafenib |
R01-900 |
284461-73-0 |
C21H16ClF3N4O3 |
>99% (TLC); NMR (Conforms) |
1. 4-(4-(3-(4-chloro-3 (trifluoromethyl) phenyl) ureido) phenoxy)-N-methylpicolinamide
2. BAY 43-9006
|
SP-600125 |
M33-900 |
129-56-6 |
C14H8N2O |
>98% (TLC); NMR (Conforms) |
1. Anthra [1-9-cd] pyrazol-6(2H)-one
2. 1,9-Pyrazoloanthrone |
Src I1 |
S19-901 |
179248-59-0 |
C22H19N3O3 |
≥98% (TLC; 5% CH3OH in CH2Cl2; Rf=0.43); NMR (Conforms) |
6,7-Dimethoxy-N-(4-phenoxyphenyl)-4-quinazolinamine |
SRPIN340 |
S21-901 |
218156-96-8 |
C18H18F3N3O |
>98% (TLC); NMR (Conforms) |
N-[2-(1-Piperidinyl)-5-(trifluoromethyl)phenyl]-4-pyridinecarboxamide |
Staurosporine |
K10-900 |
62996-74-1 |
C28H26N4O3 |
>98% (TLC); NMR (Conforms) |
|
STO-609 |
C17-900 |
52029-86-4 |
C19H10N2O3 ∙ CH3COOH |
98% (TLC); NMR (Conforms) |
7-oxo-7H-benzimidazo[2,1-a]benz[de]isoquinoline-3-carboxylic acid acetate |
SU-1498 |
F11-900E |
168835-82-3 |
C25H30N2O2 |
>98% (TLC); NMR (Conforms) |
(E)-N-(3-Phenylpropyl)-alpha-cyano-3',5'-diisopropyl-4'-hydroxycinnamamide |
SU-4312 |
F11-900F |
5812-07-7 |
C17H16N2O |
>98% (TLC); NMR (Conforms) |
1. 3-(4-Dimethylaminobenzylidene)-1,3-dihydroindol-2-one
2. DMBI |
Sunitinib malate |
F11-900G |
341031-54-7 |
C22H27FN4O2 ∙ C4H6O5 |
>98% (TLC); NMR (Conforms) |
1. N-[2-(Diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide malate
2. SU-11248 |
TG003 |
C57-901 |
719277-26-6 |
C13H15NO2S |
>98% (HPLC); NMR (Conforms) |
(Z)-1-(3-Ethyl-5-methoxy-2,3-dihydrobenzothiazol-2-ylidene)propan-2-one |
U-0126 |
M02-901 |
109511-58-2 |
C18H16N6S2 |
>98% (TLC); NMR (Conforms) |
1,4-Diamino-2,3-dicyano-1,4-bis [2-aminophenylthio] butadiene |
Vandetanib |
F11-900 |
443913-73-3 |
C22H24BrFN4O2 |
>98% (TLC); NMR (Conforms) |
1. 4-(4-Bromo-2-fluoroanilino)-6-methoxy-7-[(1-methylpiperidin-4-yl) methoxy] quinazoline
2. ZD6474 |
Vatalanib 2HCl |
F11-900D |
212141-51-0 |
C20H15CIN4•2HCl |
>98% (TLC); NMR (Conforms) |
1. N-(4-Chlorophenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine dihydrochloride
2. CGP-79787
3. PTK-787
4. ZK222584 |
VX-702 |
M39-900D |
745833-23-2 |
C19H12F4N4O2 |
>98% (HPLC); NMR (conforms) |
6-[(Aminocarbonyl)(2,6-difluorophenyl)amino]-2-(2,4-difluorophenyl)-3-pyridinecarboxamide |
WHI-P131 |
J03-901 |
202475-60-3 |
C16H15N3O3 ∙ HCl |
>98% (TLC); NMR (Conforms) |
1. 4-[(4'-hydroxyphenyl)amino]-6,7-dimethoxyquinazoline, Hydrochloride
2. Janex-1
|
Wortmannin |
P27-900B |
19545-26-7 |
C23H24O8 |
>98% (TLC); NMR (Conforms) |
11-(acetyloxy)-1S,6bR,7,8,9aS,10,11R,11bR-octahydro-1-(methoxymethyl)-9a,11b-dimethyl-3H-furo[4,3,2-de]indeno[4,5-h]-2-benzopyran-3,6,9-trione |
Y-27632 2HCl |
R10-900B |
129830-38-2 |
C14H21N3O ∙ 2HCl |
99% (HPLC); NMR (Conforms) |
(R)-(+)-trans-4-(1-Aminoethyl)-N-(-4-pyridyl) cyclohexanecarboxamide dihydrochloride |
ZM-306416 |
F11-900B |
690206-97-4 |
C16H13ClFN3O2 |
>98% (TLC); NMR (Conforms) |
4-[(4'-Chloro-2'-fluoro) phenylamino]-6,7-dimethoxyquinazoline |
ZM-336372 |
R01-901 |
331771-20-1 |
C23H23N3O3 |
98% (TLC); NMR (Conforms) |
3-(Dimethylamino)-N-[3-[(4-hydroxybenzoyl)-amino]-4-methylphenyl]-benzamide |
ZM-447439 |
A31-901 |
331771-20-1 |
C29H31N5O4 |
>98% (TLC); NMR (Conforms) |
(N-[4-[[6-Methoxy-7-[3-(4-morpholinyl) propoxy]-4-quinazolinyl] amino] phenyl] benzamide |